newsfilter
← Latest News
GlobeNewswire·

Olema Oncology Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

On-track to report top-line data in the fall of 2026 from the pivotal Phase 3 OPERA-01 trial of palazestrant as a monotherapy in patients with 2/3L ER+/HER2- metastatic breast cancerAdvanced enrollment in the OPERA-02